Related Experiment Video

Updated: Apr 28, 2026

Osmotic Minipump Implantation for Increasing Glucose Concentration in Mouse Cerebrospinal Fluid
06:21

Osmotic Minipump Implantation for Increasing Glucose Concentration in Mouse Cerebrospinal Fluid

Published on: April 7, 2023

2.2K

Repurposing diabetes drugs for brain insulin resistance in Alzheimer disease

Mark Yarchoan1, Steven E Arnold2

  • 1Department of Medicine, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA.

Diabetes
|June 17, 2014
PubMed

Insights

Type 2 diabetes (T2DM) and Alzheimer disease (AD) are linked, suggesting T2DM drugs may help AD. Further trials are needed to confirm if diabetes medications benefit AD patients.

Area of Science:

  • Neuroscience
  • Endocrinology
  • Gerontology

Background:

  • Emerging research links type 2 diabetes (T2DM) and Alzheimer disease (AD), two prevalent aging-related conditions.
  • The exact nature of this association remains unclear, prompting investigation into shared biological pathways.
  • Advances in T2DM therapies offer potential avenues for AD intervention.

Purpose of the Study:

  • To review the evidence linking T2DM and AD, focusing on common cellular and molecular mechanisms.
  • To evaluate the potential of current and developing T2DM drugs in treating AD pathophysiology and cognitive decline.
  • To highlight the need for clinical trials assessing diabetes drugs for AD treatment and prevention.

Main Methods:

  • Literature review of clinical and epidemiological studies on T2DM and AD.
  • Analysis of shared cellular and molecular pathways implicated in both diseases.
  • Assessment of clinical-stage diabetes drugs for their relevance to AD treatment.

Main Results:

  • Significant evidence supports a link between T2DM and AD.
  • Shared biological mechanisms, including inflammation and insulin resistance, are identified.
  • Several T2DM drugs show promise for AD intervention based on preclinical and early clinical data.

Conclusions:

  • The T2DM-AD link warrants further investigation into shared pathophysiological mechanisms.
  • Diabetes medications represent a promising therapeutic strategy for AD, potentially offering benefits beyond glycemic control.
  • Clinical trials are essential to validate the efficacy of T2DM drugs in managing AD and improving cognitive function.

More Related Videos

Motor and Hippocampal Dependent Spatial Learning and Reference Memory Assessment in a Transgenic Rat Model of Alzheimer's Disease with Stroke09:45

Motor and Hippocampal Dependent Spatial Learning and Reference Memory Assessment in a Transgenic Rat Model of Alzheimer's Disease with Stroke

Published on: March 22, 2016

9.8K
Intracerebroventricular Injection of Amyloid-β Peptides in Normal Mice to Acutely Induce Alzheimer-like Cognitive Deficits08:01

Intracerebroventricular Injection of Amyloid-β Peptides in Normal Mice to Acutely Induce Alzheimer-like Cognitive Deficits

Published on: March 16, 2016

42.4K

Related Concept Videos

Alzheimer's Disease: Treatment01:22

Alzheimer's Disease: Treatment

Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
1.3K
Oral Hypoglycemic Agents: Biguanides and Glitazones01:26

Oral Hypoglycemic Agents: Biguanides and Glitazones

Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood...
990
Glucagon-like Receptor Agonists01:24

Glucagon-like Receptor Agonists

Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
1.3K
Alzheimer's Disease: Overview01:26

Alzheimer's Disease: Overview

Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
1.7K
Alzheimer Disease l: Introduction01:29

Alzheimer Disease l: Introduction

Alzheimer disease is a chronic, progressive, and irreversible neurodegenerative disorder and the most common cause of dementia in older adults. It leads to gradual neuronal loss, causing cognitive decline, behavioral changes, and loss of functional independence.Risk Factors and EtiologyThe disease is multifactorial. Age is the strongest risk factor, with prevalence doubling every 5 years after age 65. Genetic factors include mutations in genes such as APP, PSEN1, and PSEN2, which are associated...
20
Dipeptidyl Peptidase 4 Inhibitors01:23

Dipeptidyl Peptidase 4 Inhibitors

Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...
1.1K